Research programme: hepatitis C therapeutics - REPLICorAlternative Names: Amphipathic DNA polymers - REPLICor; Hepatitis C programme - REPLICor; Phosphorothioate oligonucleotides - REPLICor; PS-ONs - REPLICor; REP 9C
Latest Information Update: 16 Jul 2016
At a glance
- Originator REPLICor
- Mechanism of Action Viral fusion protein inhibitors; Virus internalisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Canada (PO)